|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Purified fusion proteins induced serotype-specific neutralizing antibodies without cross-reaction against other serotypes and arboviruses after mouse immunization. hydrophobin-fused domain III of dengue envelope protein could be a promising strategy for easy and low-cost production of components of a tetravalent sub-unit vaccine against dengue.
|
31828570 |
2020 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
A star-shaped DNA architecture, carrying five molecular beacon-like motifs, was constructed to display ten dengue envelope protein domain III (ED3)-targeting aptamers into a two-dimensional pattern precisely matching the spatial arrangement of ED3 clusters on the dengue (DENV) viral surface.
|
31767992 |
2020 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, the consensus dengue virus envelope protein domain III fused to hydrophobin I of Trichoderma reesei was expressed in Pichia pastoris cultures and an in situ product removal by an ATPS using a non-ionic detergent, (Triton X-114) was performed.
|
30240632 |
2019 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we focused on the Dengue viral envelope protein (E); computational analyses ranging from extensive Molecular Dynamics (MD) simulations and energy-decomposition-based prediction of potentially immunoreactive regions identified putative epitope sequences.
|
31003530 |
2019 |
|
Dengue Fever
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, two highly conserved regions of dengue envelope protein were identified and an scFv was constructed against it.
|
30629625 |
2019 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated four types of recombinant envelope protein domain III (DV-rED III) derived from four dengue virus (DENV) serotypes for diagnostic potential in detecting IgM in acute phase (mainly 2-3 days after onset of fever).
|
31311082 |
2019 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
The virtual approach was based on generating different docking cycles of tetra, penta, hexa, and heptapeptide libraries by maximizing the discrimination between the amino acid motif in the ZIKV and dengue virus (DENV) envelope protein glycosylation site.
|
31533374 |
2019 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Zika (ZIKV) and dengue (DENV) virus infections elicit a robust but cross-reactive antibody response against the viral envelope protein, while antibody responses against non-structural proteins (NS) are more virus specific.
|
30902827 |
2019 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Small molecules that target the dengue virus envelope protein, E, on the surface of the virion could act analogously to antibodies by engaging E extracellularly to block infection; however, a shortage of target-based assays suitable for screening and medicinal chemistry studies has limited efforts in this area.
|
30027735 |
2018 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results provide insight into immunogen design strategies based on EDIII.<b>IMPORTANCE</b> Dengue virus causes approximately 390 million infections per year.
|
29976679 |
2018 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
The envelope protein (E protein) of dengue virus is responsible for a wide range of biological activities, including binding to host cell receptors and fusion to and entry into host cells.
|
29470620 |
2018 |
|
Dengue Fever
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite antigenic similarities with dengue viruses, structural studies have suggested the extended CD-loop and hydrogen-bonding interaction network within the ZIKV envelope protein contribute to stability differences between the viral families.
|
28968838 |
2017 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present work, we have targeted the domain I/III hinge region using four known ligands used for the dengue envelope protein (serotype-2) and have intended to explore the specificity of one ligand R1 (5-(3-chlorophenyl)-N-(2-phenyl-2H-benzo[d][1,2,3]triazol-6-yl)furan-2-carboxamide) that succeeded the dengue inhibition by the molecular dynamics (MD) simulations in conjunction of the molecular docking and the binding free energy calculations.
|
28255859 |
2017 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers.
|
28674411 |
2017 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Suppressive effect of dengue virus envelope protein domain III on megakaryopoiesis.
|
28622093 |
2017 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Total and Envelope Protein-Specific Antibody-Secreting Cell Response in Pediatric Dengue Is Highly Modulated by Age and Subsequent Infections.
|
27560782 |
2016 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of Global Consensus of Dengue Virus Envelope Glycoprotein for Epitopes Based Vaccine Design.
|
26022067 |
2015 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Atomic-level functional model of dengue virus Envelope protein infectivity.
|
24158478 |
2013 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interaction and inhibition of dengue envelope glycoprotein with mammalian receptor DC-sign, an in-silico approach.
|
23527139 |
2013 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
The envelope protein (E) of dengue virus binds to receptors present on the host cells through its domain III that has been primarily recognized to bind cell receptors.
|
24324976 |
2013 |
|
Dengue Fever
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dengue-1 envelope protein domain III produced in Pichia pastoris: potential use for serological diagnosis.
|
23993978 |
2013 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
It was previously reported that DIIIC-2 (a fusion protein composed of domain III of the envelope protein and the capsid protein from dengue 2 virus), as an aggregate antigen from a partially purified preparation, induced a functional protective immune response against dengue 2 virus in the mouse encephalitis model.
|
22983185 |
2013 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recombinant fusion protein containing domain III of the dengue envelope protein fused to capsid protein from dengue 2 virus was immunogenic and conferred protection in mice against lethal challenge in previously report.
|
22554934 |
2012 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Envelope protein gene sequences of all four dengue serotypes (DENV-1-DENV-4) obtained from human sera in Singapore (2008-2010) revealed that constant viral introductions and in situ evolution contribute to viral diversity in Singapore and play important roles in shaping the epidemiology of dengue in the island state.
|
22036707 |
2012 |
|
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Letter to the editor: molecular genotyping of Dengue Virus Types 2 and 4 from the Guatemalan and Honduran Epidemics of 2007 using the envelope glycoprotein gene.
|
21234665 |
2011 |